SRN-101
Recurrent High-Grade Glioma
Key Facts
About Siren Biotechnology
Siren Biotechnology is a private, pre-revenue company creating a new therapeutic modality that merges AAV gene delivery with cytokine immunotherapy to fight solid tumors. The company has transitioned to a clinical-stage entity with its first IND cleared by the FDA in early 2026 and its lead program, SRN-101, receiving Fast Track Designation for recurrent high-grade glioma. Siren's strategy is to first address the high-unmet-need area of brain cancer as a proving ground for its platform, with the long-term vision of establishing AAV immuno-gene therapy as a cornerstone treatment for any solid tumor. The company is leveraging its scientific expertise in viral technology and immuno-oncology to overcome historical challenges in these fields.
View full company profileTherapeutic Areas
Other Recurrent High-Grade Glioma Drugs
| Drug | Company | Phase |
|---|---|---|
| DB107 (Toca 511 & Toca FC) | Denovo Biopharma | Phase 2/3 |
| NanO₂ | NuvOx Therapeutics | Phase II |
| DSP-0390 | Sumitomo Pharma | Phase 1/2 |
| CAN-3110 | Candel Therapeutics | Phase 1 |